We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+11.51%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$345M
AUM Growth
+$902K
(+0.26%)
Cap. Flow
-$15.5M
Cap. Flow
% of AUM
-4.49%
Top 10 Holdings %
Top 10 Hldgs %
50.71%
Holding
65
New
21
Increased
9
Reduced
14
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mettler-Toledo International
MTD
|
+$4.19M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$3.84M |
| 3 |
Becton Dickinson
BDX
|
+$3.81M |
| 4 |
AstraZeneca
AZN
|
+$3.51M |
| 5 |
Biogen
BIIB
|
+$3.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$4.64M |
| 2 |
Cigna
CI
|
+$4.04M |
| 3 |
Zimmer Biomet
ZBH
|
+$3.94M |
| 4 |
West Pharmaceutical
WST
|
+$3.94M |
| 5 |
Quest Diagnostics
DGX
|
+$3.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVO
26
Novo Nordisk
NVO
$203B
| $3.82M | 1.11% |
+75,000
| New | +$3.84M |
|
|
27
AstraZeneca
AZN
$246B
| $3.68M | 1.07% |
+20,000
| New | +$3.51M |
|
28
Bio-Rad Laboratories Class A
BIO
$9.68B
| $3.64M | 1.06% |
12,000
+1,000
| +9% | +$312K |
|
|
29
Biogen
BIIB
$30.9B
| $3.52M | 1.02% |
+20,000
| New | +$3.27M |
|
30
Globus Medical
GMED
$11.5B
| $3.49M | 1.01% |
+40,000
| New | +$3.04M |
|
31
Merck
MRK
$328B
| $3.16M | 0.92% |
+30,000
| New | +$2.82M |
|
32
Surgery Partners
SGRY
$2B
| $3.09M | 0.9% |
200,000
-20,000
| -9% | -$368K |
|
33
Gilead Sciences
GILD
$168B
| $3.07M | 0.89% |
+25,000
| New | +$3.04M |
|
34
Bruker
BRKR
$9.03B
| $3.06M | 0.89% |
65,000
+5,000
| +8% | +$211K |
|
35
Edwards Lifesciences
EW
$53.6B
| $2.98M | 0.87% |
+35,000
| New | +$2.87M |
|
36
GE HealthCare
GEHC
$32.6B
| $2.87M | 0.83% |
35,000
+10,000
| +40% | +$779K |
|
|
SEM
37
DELISTED
Select Medical
SEM
| $2.82M | 0.82% |
190,000
+15,000
| +9% | +$212K |
|
38
Bio-Techne
TECH
$11.3B
| $2.65M | 0.77% |
+45,000
| New | +$2.73M |
|
39
CG Oncology
CGON
$6.82B
| $1.45M | 0.42% |
+35,000
| New | +$1.45M |
|
40
argenx
ARGX
$54.8B
| $1.26M | 0.37% |
+1,500
| New | +$1.28M |
|
41
Alnylam Pharmaceuticals
ALNY
$29.9B
| $1.19M | 0.35% |
+3,000
| New | +$1.33M |
|
|
42
Cigna
CI
$73.3B
| – | – |
-14,000
| Closed | -$4.04M |
|
|
43
Quest Diagnostics
DGX
$26.3B
| – | – |
-20,000
| Closed | -$3.81M |
|
|
44
Johnson & Johnson
JNJ
$629B
| – | – |
-25,000
| Closed | -$4.64M |
|
45
Labcorp
LH
$26.2B
| – | – |
-10,000
| Closed | -$2.87M |
|
46
Stevanato
STVN
$5.8B
| – | – |
-85,000
| Closed | -$2.19M |
|
|
47
West Pharmaceutical
WST
$24.8B
| – | – |
-15,000
| Closed | -$3.94M |
|
|
48
Zimmer Biomet
ZBH
$18.7B
| – | – |
-40,000
| Closed | -$3.94M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q4 2025 Portfolio in Review
As of Q4 2025, Sivik Global Healthcare held 65 positions worth $345M, up 0.26% from $344M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Sivik Global Healthcare withdrew a net $15.5M in Q4 2025, closing 16 positions and reducing 14 holdings. Its most notable exit was Johnson & Johnson, an estimated $4.64M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 48% a quarter earlier.
Against the trend, Sivik Global Healthcare opened a new position in Mettler-Toledo International worth $4.18M.
- Sivik Global Healthcare's largest Q4 2025 buy was Mettler-Toledo International: 3,000 shares worth $4.18M.
- Sivik Global Healthcare added most to Encompass Health in Q4 2025, an estimated $1.74M increase.
- Sivik Global Healthcare's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $2.87M.
- Sivik Global Healthcare fully exited Johnson & Johnson in Q4 2025, selling an estimated $4.64M.
- Sivik Global Healthcare's ten largest holdings make up 51% of its $345M portfolio in Q4 2025.
- Sivik Global Healthcare opened 21 new positions and closed 16 in Q4 2025.
- Sivik Global Healthcare's portfolio value rose 0.26% quarter-over-quarter to $345M.
Based on Sivik Global Healthcare's 13F filing for Q4 2025, filed 21 Jan 2026.